U.S. stocks drifted lower in this week, as investors digested early fourth‑quarter earnings, stubbornly mixed inflation data, and a Treasury market that seems determined to remind everyone that “higher for longer” is still a thing, even if no one wants to RSVP. The S&P 500 slipped about 0.4% for the week, the Dow edged down roughly 0.3%, and the tech‑heavy Nasdaq lost about 0.7%, while the small‑cap Russell 2000 cheerfully ignored the gloom and climbed around 2%, extending a striking run of outperformance and closing at record territory. Early‑cycle vibes in small caps contrasted with a pause in the mega‑cap trade, as investors rotated around the equity style box in search of what still looks cheap in a market that increasingly does not.
On the macro front, the economic calendar was short on quantity but long on interpretation, thanks in no small part to the lingering effects of the now‑ended 43‑day federal government shutdown that has left key data releases playing catch‑up. November producer prices, delayed by the shutdown, showed a moderate 0.1% monthly gain and a 3.0% year‑over‑year increase, while December CPI, also distorted by missing October inputs, rose about 0.3% on the month and 2.7% from a year earlier, reinforcing the view that disinflation is ongoing but no longer linear. Fed officials, for their part, stayed in pre‑meeting mode: the January FOMC gathering is scheduled for January 27–28, with the Beige Book already released on January 14, and speeches from senior policymakers repeatedly emphasized that balance‑sheet normalization has already shifted into a reserve‑management phase and that no imminent policy pivot should be inferred from the Fed’s recent technical adjustments. The Treasury curve inched bear‑steeper, with the 2‑year yield pushing toward roughly 3.6% and the 10‑year around 4.2%, reflecting slightly higher rate expectations and some term‑premium rebuilding as investors reassessed the timing and depth of eventual cuts. In the background, the prior shutdown’s impact still rippled through the calendar, with economists and traders alike parsing each release less for perfection and more for direction.
Policy and politics remained firmly in the market’s line of sight. The Trump administration’s broad tariff regime continued to filter through inflation and corporate commentary, with economists noting that December’s CPI report likely captured more of the cumulative impact of elevated import duties, even as many businesses have absorbed part of the cost to maintain margins and market share. The federal government shutdown has ended, but the data backlog remains, and the episode has become another variable in the inflation narrative, as statisticians literally interpolate missing price changes from the autumn while markets attempt to extrapolate future Fed moves from imperfect information—an exercise that may be good for bond volatility if not for anyone’s blood pressure. For now, there were no fresh, market‑moving tariff escalations or new shutdown scares this week, leaving investors to focus on earnings, the January 28 FOMC decision, and the slow return of a “normal” data flow that looks anything but.
In commodities and crypto, the store‑of‑value crowd enjoyed another week in the sun—albeit one filtered through the soft glow of trading screens. Spot gold and silver hovered near record territory, extending their powerful rallies from 2025 as investors balanced disinflation with persistent geopolitical and fiscal worries; both metals approached or exceeded prior all‑time highs intraday before closing a bit off the peaks, a pattern that suggests profit‑taking rather than fading conviction. Crude oil, by contrast, gave back earlier gains, with Brent settling in the low‑to‑mid‑60‑dollar range and WTI in the high‑50s per barrel as some geopolitical risk premium bled out after signs of de‑escalation in recent U.S.–Iran tensions and amid the first Venezuelan oil sales under the new U.S. policy framework. Bitcoin, never one to underperform in the drama department, surged through the mid‑$90,000s and briefly above $97,000, riding a wave of regulatory optimism, institutional adoption chatter, and a renewed appetite for speculative risk—leaving traditional “safe havens” looking positively understated by comparison.
Among individual names, Eli Lilly spent the week as a reminder that even market darlings occasionally encounter gravity: shares traded around the low‑$1,000s and fell roughly 3–4% midweek after reports that the FDA delayed its decision on Lilly’s closely watched oral GLP‑1 obesity pill, orforglipron, and as a fresh antitrust suit targeted the GLP‑1 market’s dominant players. The news injected a dose of uncertainty into Lilly’s incretin‑fuelled growth story, even as analysts largely maintained constructive views in light of strong Q4 sales momentum for Mounjaro and Zepbound and highlighted a high‑profile, roughly $1 billion AI drug‑discovery tie‑up with NVIDIA as a longer‑term catalyst. Chip and AI‑linked bellwethers were again central to the tape: NVIDIA remained under a spotlight of bullish broker commentary and prominent “top calls” lists, while Taiwan Semiconductor’s broader foundry narrative—benefiting from sustained AI and high‑performance computing demand—kept it firmly embedded in discussions about the sector’s 2026 capex cycle. Apple, Tesla, Palantir, Broadcom, Micron, Intel, Oracle, Meta, and other large‑cap tech and AI‑adjacent names all featured heavily in options and analyst chatter, reflecting a market that may be taking a breather in price action but is still very much obsessed with figuring out which part of the AI stack will deserve the next valuation upgrade. In the broader corporate landscape, M&A expectations for 2026 remained high following a strong rebound in large deals last year, with recent commentary highlighting blockbuster tie‑ups across telecom, software, and infrastructure—such as Netflix’s pending purchase of Warner Bros. Discovery and a string of multibillion‑dollar strategic and sponsor‑backed transactions—though no new mega‑deals this week rivaled those December headlines.
The primary markets, while hardly euphoric, showed more vital signs than in recent years. One small operating company IPO and three SPACs priced in the U.S. this week, while eight additional IPOs, including several larger offerings, joined the pipeline with fresh filings, giving bankers a little more to talk about than their golf handicaps. On the ETF front, the Nasdaq calendar showed new BNY Mellon municipal fixed‑income ETFs among the latest listings, underscoring the ongoing shift of retail and advisory flows toward lower‑cost vehicles even as traditional IPOs cautiously re‑emerge. Dealmakers’ outlook pieces highlighted robust M&A pipelines across energy, telecom, and technology heading into 2026, with upcoming transactions in sectors ranging from AI infrastructure to renewable utilities, even if this particular week’s tape was dominated more by positioning than by splashy new announcements. Against that backdrop, the major equity benchmarks’ modest declines, the Russell 2000’s quiet heroism, and the unmistakable bid in gold, silver, and Bitcoin suggested a market that is not so much risk‑off as it is risk‑reallocated—a kind of sophisticated game of musical chairs where the music has slowed, but nobody seems quite ready to leave the room.
Vista Partners Watchlist Updates
Modular Medical, Inc. (Nasdaq: MODD., $.475), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, announced (Dec. 10) that it had priced an underwritten public offering (the “offering”) of 12,173,000 shares of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock. Each two shares of common stock are being offered and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance. In connection with the offering, Modular Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of common shares and/or warrants at the public offering price, less underwriting discounts and commissions. The over-allotment option may be elected with respect to, at the underwriter’s sole discretion, shares and warrants together, solely shares, solely warrants, or any combination thereof. Newbridge Securities Corporation is acting as the sole bookrunner for the offering. Assuming no exercise of the over-allotment option, the gross proceeds to the Company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts, commissions, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures.
On Nov. 17, Modular announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.
On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $8.20, +1.44%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated,“These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”
GeoVax Labs, Inc. (Nasdaq: GOVX, $2.99), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer.
On Jan. 15, Portal Innovations announced continued growth at Portal Atlanta at Science Square, with the addition of seven new member companies, bringing the total ecosystem to 32 biotech, medtech, digital health, and cleantech, organizations served, just 15 months after launch. The milestone – which includes 7 new members in just the month of January 2026 alone – highlights the rapid momentum building around Science Square and Atlanta’s expanding life sciences and medtech community. Since opening, Portal Atlanta has quickly become a home for startups advancing medical devices, innovation, cleantech, and life sciences technologies. Recent growth has also been supported by the addition of established corporate innovators, including Duracell and GeoVax, which recently joined Portal’s ecosystem and brings deep expertise in power, hardware, biotech, and product development. Additionally, Portal’s ecosystem has expanded into cleantech innovation with a new member, the Georgia Cleantech Innovation Hub.
GeoVax is heading into the 44th Annual J.P. Morgan Healthcare Conference week (“JPM2026”) in San Francisco, CA Jan. 12-15 with the kind of narrative biotech investors typically like to hear: a differentiated platform, large funded trials lining up, and multiple shots on goal in both infectious disease and oncology. The company is leaning into its MVA platform as a potential franchise engine rather than a one‑product science experiment. Specifically, investors can meet David Dodd, Chairman & CEO of GeoVax, during his presentation at the Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA on January 13, 2026, 2:30 pm PST.
GeoVax announced (Dec. 19) that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $3.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 22, 2025, subject to the satisfaction of customary closing conditions.
GeoVax announced (Dec. 18) the publication of a peer-reviewed article in Frontiers in Immunology titled: “Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.” The study provides definitive preclinical evidence that GeoVax’s multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, delivers full cross-variant protection, driven predominantly by robust T-cell responses, even in the absence of neutralizing antibodies. The findings reinforce the design philosophy behind GeoVax’s MVA-based, multi-antigen platform and provide mechanistic insight that is increasingly relevant for immunocompromised individuals, who often fail to respond optimally to the first-generation COVID-19 vaccines.
GeoVax announced (Dec. 17) the successful completion of fill-finish for the initial clinical batch of GEO-MVA, its next-generation Mpox/smallpox vaccine. The product has now entered final release evaluation, the concluding quality-control and compliance process required before shipment for clinical use, positioning the Company for Phase 3 immunobridging trial start-up activities in Q1 2026. Fill-finish – the sterile, cGMP-regulated process of filling, sealing, and packaging vaccine vials – marks the last manufacturing step before a vaccine may enter clinical study supply channels. With fill-finish complete and GEO-MVA now undergoing final release evaluation, GeoVax has moved into the final pre-clinical-deployment phase of its EMA-aligned clinical program. In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex(R), would be sufficient to evaluate GEO-MVA’s efficacy. This provides a clear, accelerated regulatory path to licensure. This milestone coincides with increasing Mpox activity globally – including expanding Clade I outbreaks in Africa and emerging cases in the United States – exposing vulnerabilities associated with global dependence on a sole foreign MVA vaccine supplier. GEO-MVA is designed to expand supply, diversify sources, and strengthen biodefense infrastructure.
Volato Group, Inc. (NYSE American: SOAR, $.5423) and M2i Global, Inc. (MTWO, $.0599), a company specializing in the development and execution of a complete global value supply chain for critical minerals, recently announced key developments in its pending all-stock merger with M2i Global, Inc.. Volato has filed the Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”), following the SEC’s completion of its review of the initial confidential submission. With the reopening of federal agencies following the recent government shutdown, both companies now anticipate closing the merger in the first quarter of 2026, pending completion of SEC review and shareholder approval.
On Jan. 9, M2i Global and Volato Group announced that they have entered into a strategic collaboration agreement with Australian company Titanium X to advance critical mineral development in the US. This partnership represents a significant move towards enhancing domestic refining capacity and strengthening the critical materials supply chain that underpins US industry and national security. Titanium X and M2i Global will work together on the financing, development and commercialisation of the former’s critical mineral assets. M2i Global will apply its global experience in delivering mineral projects to support these initiatives. The companies are also in talks to conclude an exclusive titanium concentrate supply agreement.
On Jan. 7, M2i Global, Inc. along with Volato Group, Inc. (“Volato”) (NYSE American: SOAR), a technology-driven company, announced a strategic collaboration agreement with Titanium X, marking a major step forward in advancing domestic refining capabilities and securing the critical materials supply chain essential to U.S. industry and national security.
Volato Group, Inc. today (Dec. 29) announced the appointment of Alan D. Gaines to its Board of Directors, effective immediately. Mr. Gaines will also serve as Chairman of the Audit Committee.
On Dec. 23, Volato Group, Inc. announced preliminary financial guidance for the fourth quarter and full year ending December 31, 2025, reflecting continued execution against its strategic and balance sheet objectives. For the fourth quarter of 2025, Volato expects to report revenue between $27 million and $28 million. For the full year 2025, the Company anticipates total revenue between $78 million and $79 million, with net income of $6 million to $8 million. These results reflect a year of meaningful progression aligning operational performance with Volato’s long-term growth initiatives and advancing its pending merger with M2i Global, Inc. (OTC: MTWO). During 2025, Volato also made substantial progress strengthening its balance sheet. As of September 30, 2025, the Company reduced total liabilities to $9.5 million, satisfying the debt reduction condition required under its pending merger agreement with M2i Global, Inc. (OTC: MTWO). Volato expects continued improvement in its capital structure as it advances toward a targeted first-quarter 2026 closing of the transaction. “Our 2025 results reflect a year of transformation and disciplined balance sheet execution,” said Mark Heinen, Chief Financial Officer of Volato. “We made significant progress reducing liabilities while sharpening our focus on scalable, technology-driven businesses that are designed to complement and strengthen the M2i Global platform over the long term.”
Volato Group, Inc. announced recently that it has set a preliminary date of February 26, 2026 and preliminary record date of January 17, 2026 for a special meeting of shareholders to vote on the proposed merger with M2i Global, Inc. (MTWO) and related matters. The preliminary meeting date and record date remain subject to applicable regulatory and exchange requirements, including the effectiveness of Volato’s Registration Statement on Form S-4 (File No. 333-292132) (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (“SEC”) and the mailing of definitive proxy materials to shareholders. The proposed merger creates a combined company built for scale. M2i Global brings a platform focused on critical minerals and national supply chain resilience, while Volato contributes proven aviation technology, software capability, and an established track record of operational execution. Together, the companies aim to participate in a U.S. critical minerals market estimated at more than $320 billion annually.
Critical Metals Corp. (CRML, $17.65, +17.86% over the last 5-days), a leading critical minerals mining company,today announced that the first assay results from the 2025 drilling program have been received from the Fjord Deposit and Upper Fjord areas at the Tanbreez Rare Earths Project in Greenland.
Serina Therapeutics (NYSE American: SER, $3.10 +22.05% over the last 5-days, Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies. On Dec. 11, Serina announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development.
On Dec. 10, Serina announced that it has submitted a complete response to the U.S. Food and Drug Administration’s (“FDA”) clinical hold letter for SER-252, the Company’s lead program for advanced Parkinson’s disease. As previously disclosed, the FDA placed the Company’s Investigational New Drug (“IND”) application for SER-252 on clinical hold pending additional information related to a commonly used formulation excipient. On November 25, 2025, the FDA issued a formal full clinical hold letter specifying the information required to permit initiation of the planned Phase 1b registrational study, SER-252-1b. The issues identified by the FDA do not relate to the apomorphine active drug substance, its mechanism of action, the use of the enFuse device (Enable Injections) or the broader 505(b)(2) NDA development pathway previously discussed with the Agency.
The InterGroup Corporation (NASDAQ: INTG, $28.62, +2.76% over the last 5-days) announced (Jan. 6) that on December 29, 2025, it completed the sale of a non-core 12-unit apartment complex in Los Angeles County for a gross sales price of approximately $4,850,000. InterGroup expects to report a GAAP net gain on sale of approximately $3,509,000, which will be reflected in the Company’s Form 10‑Q for the quarter ended December 31, 2025. The transaction is expected to result in federal and state income tax liability, the amount of which will be determined based on the Company’s final tax position and applicable tax rules.
DoubleVerify Holdings Inc. (DV) closed at $10.49. DoubleVerify, which built its franchise on media verification and ad performance analytics, is now the first badged TikTok Marketing Partner focused specifically on attention measurement, tapping impression-level signals from the platform. Brands gain a granular view of how exposure and user interaction come together across TikTok formats, ad sets, creatives, and objectives, effectively treating every swipe as a tiny A/B test.
flyExclusive, Inc. (NYSE American: FLYX, $3.42), one of the nation’s largest private jet operators and a certified Part 145 Repair Station, today announced it has signed an authorized dealership agreement with Starlink, becoming a certified dealer and installer for Starlink’s high-speed, low-latency aviation connectivity system.
The Sources
[1] How major US stock indexes fared Friday, 1/16/2026 https://www.theglobeandmail.com/investing/markets/commodities/RGZ25/pressreleases/37089970/how-major-us-stock-indexes-fared-friday-1-16-2026/
[2] Wall Street ends little changed before long weekend | Reuters https://www.reuters.com/business/wall-st-futures-rise-chipmakers-advance-end-choppy-week-2026-01-16/
[3] Stock Market News From Jan. 16, 2026: Dow, S&P 500, Nasdaq Fall https://www.barrons.com/livecoverage/stock-market-news-today-011626
[4] Fixed Income & Equities Markets Week in Review | January 16, 2026 https://www.watrust.com/articles/week-in-review-january-16-2026
[5] How major US stock indexes fared Friday, 1/16/2026 https://www.washingtonpost.com/business/2026/01/16/stocks-dow-jones-nasdaq/a1781dc0-f322-11f0-a4dc-effc74cb25af_story.html
[6] Calendar: January 2026 – Federal Reserve Board https://www.federalreserve.gov/newsevents/2026-january.htm
[7] Economic Calendar: These are the Government Data Reports We’re … https://www.investopedia.com/economic-calendar-these-are-the-government-data-reports-we-re-still-waiting-on-after-the-shutdown-11881832
[8] A Few Words for the New Year – Federal Reserve Bank of New York https://www.newyorkfed.org/newsevents/speeches/2026/wil260112
[9] US producer prices increase moderately in November | Reuters https://www.reuters.com/business/us-producer-prices-increase-moderately-november-2026-01-14/
[10] US consumer prices likely snapped back after being … – Reuters https://www.reuters.com/world/us/us-consumer-prices-likely-snapped-back-after-being-restrained-by-government-2026-01-13/
[11] Economic Week Ahead: Inflation, Retail Sales to Set the Tone for … https://www.investing.com/analysis/economic-week-ahead-inflation-retail-sales-to-set-the-tone-for-fed-policy-200673032
[12] EM Weekly January 17, 2026 – Gramercy – A Better Approach To EM https://www.gramercy.com/2026/01/em-weekly-january-17-2026/
[13] Bitcoin Surges, Gold Price Soars & U.S. Sells Venezuelan Oil https://us.plus500.com/en/newsandmarketinsights/bitcoin-price97k-gold-soars-us-sells-oil
[14] COT on forex and commodities – Week to 6 January 2026 – Saxo Bank https://www.home.saxo/content/articles/commodities/cot-on-forex-and-commodities—week-to-6-january-2026-12012026
[15] Dealmaker’s Digest: A Top 10 Bulletin – January 2026 | Insights https://www.ropesgray.com/en/insights/alerts/2026/01/dealmakers-digest-january-2026
[16] M&A Outlook 2026: Expectations Are High—Again | BCG https://www.bcg.com/publications/2026/m-and-a-outlook-expectations-are-high-again
[17] Wall Street bankers expect busy 2026 after cashing in on big deals https://www.dailysabah.com/business/economy/wall-street-bankers-expect-busy-2026-after-cashing-in-on-big-deals/amp
[18] LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling https://www.nasdaq.com/articles/lly-stock-falls-after-fda-reportedly-delays-obesity-drug-ruling
[19] Eli Lilly and Company (LLY) Stock Historical Prices & Data https://finance.yahoo.com/quote/LLY/history/
[20] Eli Lilly and Company (NYSE:LLY) Stock Price Down 3.8% https://www.marketbeat.com/instant-alerts/eli-lilly-and-company-nyselly-stock-price-down-38-whats-next-2026-01-15/
[21] HotOptions Report For Mid Day, January 9, 2026 – The Options Insider https://theoptionsinsider.com/news/most-active-options/hotoptions-report-for-mid-day-january-9-2026-tsla-nvda-intc-aapl-mstr-nflx-open-amzn-googl-pltr-mu-amd-meta-sofi-apld-orcl-msft-avgo-goog-smr/
[22] Lilly Eli & (LLY) Stock Price, News & Analysis https://www.stocktitan.net/overview/LLY/
[23] 3 Technology Stocks to Sell in 2026 – Yahoo Finance https://finance.yahoo.com/news/3-technology-stocks-sell-2026-163117495.html
[24] Biggest Wall Street analyst calls Thursday like Nvidia – CNBC https://www.cnbc.com/2026/01/15/biggest-wall-street-analyst-calls-thursday-like-nvidia.html
[25] Upcoming Mergers and Acquisitions in 2026 + Recent Big Deals https://dealroom.net/blog/upcoming-m-a
[26] U.S. IPO Weekly Recap: 1 Small Issuer And 3 SPACs List, As More … https://seekingalpha.com/article/4860656-us-ipo-1-small-issuer-3-spacs-list-more-big-names-join-pipeline
[27] Upcoming & Recent IPO’s – IPOs Calendar – Yahoo Finance https://finance.yahoo.com/calendar/ipo?from=2026-01-11&to=2026-01-17&day=2026-01-12
[28] Week In Review: January 12, 2026 M&A Deals – KippsDeSanto https://www.kippsdesanto.com/insights/industry-week-in-review-january-9-2026/
[29] Wall Street bankers shift focus to busy 2026 after cashing in on big … https://wtvbam.com/2026/01/15/wall-street-bankers-shift-focus-to-busy-2026-after-cashing-in-on-big-deals/
[30] M&A News: Global M&A Deals Week of January 5 to 11, 2026 https://imaa-institute.org/m-and-a-news/weekly-m-and-a-news-jan-5-11-2026/
[31] Wall Street bankers shift focus to busy 2026 after cashing in on big … https://www.reuters.com/business/finance/wall-street-bankers-shift-focus-busy-2026-after-cashing-big-deals-2026-01-15/
[32] IPOs Recently Filed – IPOScoop https://www.iposcoop.com/ipos-recently-filed/
[33] IPO Calendar – Nasdaq https://www.nasdaq.com/market-activity/ipos
[34] How major US stock indexes fared Friday, 1/16/2026 – Yahoo Finance https://sg.finance.yahoo.com/news/major-us-stock-indexes-fared-213007165.html
[35] Stock market news for Jan. 16, 2026 – CNBC https://www.cnbc.com/2026/01/15/stock-market-today-live-updates.html
[36] Top Stock Picks for Week of January 5, 2026 – Yahoo Finance https://finance.yahoo.com/news/top-stock-picks-week-january-223000571.html
[37] WEEKLY STOCK MARKET DIGEST: WHAT PRUDENT INVESTORS … https://blog.thearorareport.com/stock-market-251122/
[38] Stock Market News, Jan. 16, 2026: Trump Suggests Hassett Might … https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-01-16-2026
[39] Stock Market Overview – FS Insight https://fsinsight.com/members/market/
[40] Stock Market News Jan. 16, 2026: Dow, S&P 500 and Nasdaq all … https://www.marketwatch.com/livecoverage/stock-market-today-dow-s-p-500-and-nasdaq-point-higher-as-appetite-for-tech-stocks-set-to-continue
[41] Eli Lilly: Exceptional 2025, But Rising Headwinds Loom In 2026 https://seekingalpha.com/article/4860502-eli-lilly-exceptional-2025-but-rising-headwinds-loom-in-2026
[42] Eli Lilly: A Strong Player in the Pharmaceutical Arena https://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/37092290/eli-lilly-a-strong-player-in-the-pharmaceutical-arena/
[43] Eli Lilly shares drop 3.76% as FDA delays weight-loss drug review https://www.ainvest.com/news/eli-lilly-shares-drop-3-76-fda-delays-weight-loss-drug-review-2601/
[44] Top 10 Stocks For January 16, 2026 ( $SPHL, $CJMB … – YouTube https://www.youtube.com/watch?v=7w5ZTlRVTEc
[45] LLY Jan 2026 1010.000 call (LLY260116C01010000) https://finance.yahoo.com/quote/LLY260116C01010000/history/
